{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=45",
    "query": {
      "intervention": "Placebo; placebo comparator condition",
      "page": 45
    },
    "page_size": 10
  },
  "pagination": {
    "page": 45,
    "page_size": 10,
    "total_count": 7773,
    "total_pages": 778,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=46&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%3B+placebo+comparator+condition&page=44&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T17:30:43.589Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02805023",
      "title": "BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Limb-Threatening Ischemia",
        "Peripheral Arterial Disease",
        "Peripheral Vascular Disease"
      ],
      "interventions": [
        {
          "name": "BGC101 (autologous EnEPC preparation)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control medium",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioGenCell Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2016-06",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • New Haven, Connecticut • Baltimore, Maryland",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02805023"
    },
    {
      "nct_id": "NCT05406362",
      "title": "Assess Safety and Efficacy of VAD044 in HHT Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)"
      ],
      "interventions": [
        {
          "name": "VAD044 Part I",
          "type": "DRUG"
        },
        {
          "name": "VAD044 Part II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vaderis Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2022-07-18",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05406362"
    },
    {
      "nct_id": "NCT01674361",
      "title": "A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obsessive-Compulsive Disorder"
      ],
      "interventions": [
        {
          "name": "Bitopertin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SSRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 99,
      "start_date": "2012-12-31",
      "completion_date": "2015-04-30",
      "has_results": false,
      "last_update_posted_date": "2017-08-02",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 27,
      "location_summary": "Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more",
      "locations": [
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674361"
    },
    {
      "nct_id": "NCT00064402",
      "title": "Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Chronic Bronchitis",
        "Emphysema"
      ],
      "interventions": [
        {
          "name": "arformoterol tartrate inhalation solution",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 741,
      "start_date": "2002-04",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 65,
      "location_summary": "Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fair Oaks",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064402"
    },
    {
      "nct_id": "NCT05063201",
      "title": "Cariprazine for Comorbid Cocaine and Opioid Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid-use Disorder",
        "Cocaine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Cariprazine 1.5 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyle Kampman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2022-08-05",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05063201"
    },
    {
      "nct_id": "NCT01911442",
      "title": "Lurasidone Pediatric Autism Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autism"
      ],
      "interventions": [
        {
          "name": "Lurasidone 20 mg daily",
          "type": "DRUG"
        },
        {
          "name": "Lurasidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 150,
      "start_date": "2013-08",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-02-25",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 41,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Newport Beach, California + 38 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01911442"
    },
    {
      "nct_id": "NCT00518986",
      "title": "Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sleep Disorders",
        "Obstructive Sleep Apnea",
        "Major Depressive Disorder",
        "Dysthymic Disorder"
      ],
      "interventions": [
        {
          "name": "armodafinil",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cephalon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 249,
      "start_date": "2007-10",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2013-07-19",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 62,
      "location_summary": "Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00518986"
    },
    {
      "nct_id": "NCT05650229",
      "title": "Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Mitochondrial Disease"
      ],
      "interventions": [
        {
          "name": "KL1333",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2022-12-13",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 20,
      "location_summary": "Orange, California • San Diego, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05650229"
    },
    {
      "nct_id": "NCT05418777",
      "title": "Treatment of Pneumocystis in COPD (the TOPIC Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COPD Exacerbation Acute"
      ],
      "interventions": [
        {
          "name": "Trimethoprim Sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "40 Years to 89 Years"
      },
      "enrollment_count": 1,
      "start_date": "2022-09-28",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2023-11-29",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 1,
      "location_summary": "Royal Oak, Michigan",
      "locations": [
        {
          "city": "Royal Oak",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05418777"
    },
    {
      "nct_id": "NCT02924883",
      "title": "A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2016-09-26",
      "completion_date": "2020-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-17",
      "last_synced_at": "2026-10-16T17:30:43.589Z",
      "location_count": 15,
      "location_summary": "Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924883"
    }
  ]
}